查看購物車
  • English
封面
市場調查報告書
商品編碼
1914657

乳癌治療市場 - 全球產業規模、佔有率、趨勢、機會及預測（按治療方法類型、荷爾蒙療法、標靶治療、最終用戶、地區和競爭格局分類，2021-2031年）

Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Therapy, By Hormone Therapy, By Targeted Therapy, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球乳癌治療市場預計將從2025年的419.1億美元成長到2031年的742.9億美元，複合年成長率（CAGR）為10.01%。該市場涵蓋多種旨在對抗乳腺組織內惡性腫瘤的藥物治療方法，包括化療、荷爾蒙療法和標靶免疫療法。推動市場成長的關鍵因素是全球乳癌發生率的上升以及早期診斷篩檢計畫的廣泛應用，這些因素擴大了合格治療條件的患者群體。根據美國癌症協會預測，2025年美國女性將新增約316,950例侵襲性乳癌病例，而對有效治療方案的持續需求將確保市場穩定發展。

市場概覽
預測期 2027-2031
市場規模：2025年 419.1億美元
市場規模：2031年 742.9億美元
複合年成長率：2026-2031年 10.01%
成長最快的細分市場 標靶治療
最大的市場 北美洲

儘管前景廣闊，但由於新型生物製劑和聯合治療帶來的巨大經濟負擔，市場仍面臨許多挑戰。這些高昂的費用往往導致嚴格的報銷政策和病患用藥受限，尤其是在醫療預算有限的開發中國家。因此，這些經濟障礙仍然是一項重大挑戰，可能阻礙先進治療方法在全球範圍內的推廣應用，並限制治療市場的整體獲利能力。

市場促進因素

新一代抗體藥物偶聯物（ADC）的興起，因其能將抗癌藥物直接遞送至癌細胞，相比傳統化療具有更高的療效，成為推動收入成長的主要動力。這類療法能夠針對HER2等特定抗原，同時最大限度地降低全身毒性，從而革新了標準治療通訊協定，並迅速獲得商業性認可。這些標靶治療的經濟可行性，也推動了產業向高價值生物資產的轉型。例如，Astra Zeneca2025年2月發布的報告預測，其抗體藥物複合體EnHeart®在2024會計年度的全年銷售額將達到37.54億美元，凸顯了這些先進製劑將對整個產業產生的巨大經濟影響。

同時，全球乳癌盛行率和發病率的上升，要求在美國市場以外持續大規模生產和分銷治療藥物。不斷成長的患者群體對藥物治療（從荷爾蒙療法到創新免疫療法）產生了持續的依賴，從而確保了市場規模的穩定。根據國際癌症研究機構（IARC）於2025年2月在《自然醫學》雜誌上發表的一項研究，如果目前的趨勢持續下去，到2050年，全球新增乳癌病例預計將達到每年320萬例。這項預測，加上世界衛生組織（WHO）於2025年8月發布的報告（該報告估計，在最近一個統計週期內，全球乳癌死亡人數為67萬），凸顯了該領域治療的緊迫性和尚未滿足的需求，因此需要繼續增加對該領域的投資。

市場挑戰

先進藥物治療帶來的巨大經濟負擔是全球乳癌治療市場擴張的主要障礙。生物製藥的研發需要大量資金投入，導致其價格往往超出醫療支付者和病患的負擔能力。這種經濟差距造成了臨床應用與實際可及性之間的不平衡，因為嚴格的報銷指南經常拒絕或延遲對昂貴治療方法的報銷，尤其是在對成本敏感的地區。這導致新型高價值治療方法的普及率低下，直接限制了該領域的收入成長。

這場經濟負擔危機阻礙了市場發展，因為它將目標患者群體限制在擁有充足保險和/或大量個人資產的人群中。近期產業數據也印證了這種經濟壓力的嚴重性。根據美國臨床腫瘤學會 (ASCO) 對 2025 年經濟負擔的分析，未投保患者平均每年需花費超過 78,000 美元，這表明獲得現代醫療保健面臨嚴峻的經濟挑戰。這些高昂的費用迫使許多患者放棄最佳治療方案或轉向價格較低但較為傳統的療法，從而降低了先進療法的商業性可行性，並削弱了整個市場的財務表現。

市場趨勢

皮下注射單株抗體製劑的出現正在顯著改變乳癌的治療方式，其目標是減少醫療資源消耗並提高患者的便利性。透過以快速注射取代耗時的靜脈注射，醫療機構可以顯著減輕輸液中心的負擔，同時提高患者的治療依從性。固定劑量組合藥物的快速普及正是此一趨勢的例證。這類製劑將多種生物製藥整合到單一的皮下給藥途徑中，在簡化操作流程的同時，維持了臨床療效。例如，羅氏公司於2025年1月發布的2024年度報告顯示，其皮下注射製劑Fezgo （Pertuzumab和曲妥珠單抗的複方製劑）的銷售額達到17.4億瑞士法郎，同比成長62%，這表明市場對高效給藥方式的需求強勁。

同時，CDK4/6抑制劑在輔助性治療治療領域的應用拓展，標誌著早期荷爾蒙受體陽性乳癌治療的重大進展。除了用於轉移性疾病的治療外，這些藥物也擴大被納入標準術後治療方法，以降低高風險患者族群的復發風險。臨床實踐的這一發展使得製藥公司能夠更早針對更廣泛的患者群體，從而擴大目標市場。基於此，諾華在其策略更新中將CDK4/6抑制劑Kisqali的銷售高峰預期上調至2025年超過100億美元。此次上調直接歸功於該藥物在早期乳癌領域的強勁商業性表現。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球乳癌藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療方法（化療、荷爾蒙療法、免疫療法、標靶治療、其他）
    • 透過荷爾蒙療法（選擇性雌激素受體調節、Aromatase抑制劑等）
    • 透過標靶治療（單株抗體、蛋白酪氨酸激酶抑制劑、Herceptin等）
    • 依最終使用者（醫院、專科診所、門診手術中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美乳癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章 歐洲乳癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區乳癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲乳癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲乳癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球乳癌藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AstraZeneca PLC
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Sanofi
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 10617

The Global Breast Cancer Therapeutics Market is projected to experience significant growth, rising from a valuation of USD 41.91 billion in 2025 to USD 74.29 billion by 2031, reflecting a compound annual growth rate of 10.01%. This sector encompasses a diverse array of pharmacological treatments, such as chemotherapy, hormonal therapies, and targeted immunotherapies, all designed to combat malignant neoplasms within breast tissue. The primary force propelling this expansion is the escalating global incidence of the disease, coupled with the widespread adoption of early diagnostic screening initiatives that enlarge the eligible patient population. According to the American Cancer Society, approximately 316,950 new invasive breast cancer cases are expected to be diagnosed among women in the United States in 2025, creating a persistent demand for effective therapeutic options that ensures a stable trajectory for market development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 41.91 Billion
Market Size 2031USD 74.29 Billion
CAGR 2026-203110.01%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Despite these growth prospects, the market confronts a substantial obstacle regarding the immense financial strain associated with novel biological medications and combination therapeutic regimens. These exorbitant costs frequently lead to strict reimbursement policies and restricted patient access, especially within developing countries operating under limited healthcare budgets. Consequently, these economic hurdles persist as a major challenge that threatens to curb the worldwide adoption of sophisticated treatment modalities and limit the overall revenue capability of the therapeutics market.

Market Driver

The rise of Next-Generation Antibody-Drug Conjugates (ADCs) serves as a major revenue driver, providing enhanced efficacy compared to conventional chemotherapy by channeling cytotoxic agents directly into tumor cells. This therapeutic category has experienced rapid commercial adoption because of its capacity to target specific antigens, such as HER2, while minimizing systemic toxicity, thereby transforming standard care protocols. The financial viability of these targeted approaches confirms the industry's transition toward high-value biological assets; for instance, AstraZeneca's February 2025 report indicated that full-year sales for the antibody-drug conjugate Enhertu reached $3,754 million in FY 2024, highlighting the significant economic impact of these advanced formulations on the broader sector.

Concurrently, the escalating prevalence and incidence of breast cancer worldwide necessitate sustained large-scale production and distribution of therapeutics outside the United States market. This growing patient demographic establishes a lasting reliance on pharmaceutical treatments, spanning from hormonal interventions to innovative immunotherapies, which secures consistent market volume. According to a study published in Nature Medicine by the International Agency for Research on Cancer in February 2025, global new breast cancer cases are projected to reach 3.2 million annually by 2050 if current trends persist. This forecast, alongside the World Health Organization's August 2025 report estimating 670,000 global deaths in the latest cycle, emphasizes the critical urgency and unmet need that fuel ongoing investment in this therapeutic space.

Market Challenge

The substantial financial burden linked to advanced pharmacological treatments represents a major impediment to the expansion of the Global Breast Cancer Therapeutics Market. Since the development of biological drugs requires massive capital investment, the resulting pricing often surpasses the fiscal capacity of healthcare payers and patients alike. This economic gap creates a disparity between clinical availability and real-world accessibility, as strict reimbursement guidelines often deny or delay coverage for premium therapies, particularly in regions sensitive to costs. As a result, the adoption rates of newer, high-value treatments are suppressed, which directly limits the revenue growth trajectory of the sector.

This crisis of affordability hinders market development by narrowing the addressable patient base to individuals possessing extensive insurance coverage or significant private wealth. The severity of this economic pressure is underscored by recent industry data; according to a 2025 analysis by the American Society of Clinical Oncology regarding financial toxicity, uninsured patients encountered average annual costs surpassing $78,000, illustrating the intense fiscal difficulties associated with accessing modern care. Such prohibitive costs compel many patients to decline optimal treatment plans or resort to older, less costly alternatives, which diminishes the commercial volume of advanced therapeutics and weakens the market's overall financial performance.

Market Trends

The shift toward subcutaneous formulations of monoclonal antibodies is significantly transforming the administration of breast cancer therapies, motivated by the desire to decrease healthcare resource consumption and enhance patient convenience. By substituting lengthy intravenous infusions with quick injections, healthcare facilities can greatly reduce the strain on infusion centers while simultaneously improving treatment adherence. This trend is demonstrated by the swift adoption of fixed-dose combinations that integrate proven biologics into a single subcutaneous delivery mechanism, preserving clinical efficacy while streamlining operations; for example, Roche's 2024 Annual Report released in January 2025 noted that sales of Phesgo, a subcutaneous blend of pertuzumab and trastuzumab, jumped by 62% year-on-year to CHF 1.74 billion, signaling a robust market preference for these efficient delivery methods.

At the same time, the expansion of CDK4/6 inhibitors into adjuvant treatment settings marks a crucial advancement in the management of early-stage hormone receptor-positive disease. Transitioning beyond metastatic applications, these agents are increasingly incorporated into standard post-surgical regimens to lower recurrence risks in high-risk patient groups. This evolution in clinical practice widens the addressable market by enabling pharmaceutical firms to target a much broader patient population at earlier stages of the illness; reflecting this, Novartis raised its peak sales forecast for the CDK4/6 inhibitor Kisqali to over $10 billion in a November 2025 strategic update, directly crediting this adjustment to the drug's strong commercial uptake in the early breast cancer setting.

Key Market Players

  • AstraZeneca PLC
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Sanofi
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson

Report Scope

In this report, the Global Breast Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Therapeutics Market, By Therapy

  • Chemotherapy
  • Hormone Therapy
  • Immunotherapy
  • Targeted Therapy
  • Others

Breast Cancer Therapeutics Market, By Hormone Therapy

  • Selective Estrogen Receptor Modulators
  • Aromatase Inhibitors
  • Others

Breast Cancer Therapeutics Market, By Targeted Therapy

  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitor
  • Herceptin
  • Others

Breast Cancer Therapeutics Market, By End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

Breast Cancer Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Cancer Therapeutics Market.

Available Customizations:

Global Breast Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
    • 5.2.2. By Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
    • 5.2.3. By Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 5.2.4. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Breast Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Hormone Therapy
    • 6.2.3. By Targeted Therapy
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Breast Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Hormone Therapy
        • 6.3.1.2.3. By Targeted Therapy
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Breast Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Hormone Therapy
        • 6.3.2.2.3. By Targeted Therapy
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Breast Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Hormone Therapy
        • 6.3.3.2.3. By Targeted Therapy
        • 6.3.3.2.4. By End User

7. Europe Breast Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Hormone Therapy
    • 7.2.3. By Targeted Therapy
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Breast Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Hormone Therapy
        • 7.3.1.2.3. By Targeted Therapy
        • 7.3.1.2.4. By End User
    • 7.3.2. France Breast Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Hormone Therapy
        • 7.3.2.2.3. By Targeted Therapy
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Breast Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Hormone Therapy
        • 7.3.3.2.3. By Targeted Therapy
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Breast Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy
        • 7.3.4.2.2. By Hormone Therapy
        • 7.3.4.2.3. By Targeted Therapy
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Breast Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy
        • 7.3.5.2.2. By Hormone Therapy
        • 7.3.5.2.3. By Targeted Therapy
        • 7.3.5.2.4. By End User

8. Asia Pacific Breast Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Hormone Therapy
    • 8.2.3. By Targeted Therapy
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Breast Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Hormone Therapy
        • 8.3.1.2.3. By Targeted Therapy
        • 8.3.1.2.4. By End User
    • 8.3.2. India Breast Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Hormone Therapy
        • 8.3.2.2.3. By Targeted Therapy
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Breast Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Hormone Therapy
        • 8.3.3.2.3. By Targeted Therapy
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Breast Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Hormone Therapy
        • 8.3.4.2.3. By Targeted Therapy
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Breast Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Hormone Therapy
        • 8.3.5.2.3. By Targeted Therapy
        • 8.3.5.2.4. By End User

9. Middle East & Africa Breast Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Hormone Therapy
    • 9.2.3. By Targeted Therapy
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Breast Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Hormone Therapy
        • 9.3.1.2.3. By Targeted Therapy
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Breast Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Hormone Therapy
        • 9.3.2.2.3. By Targeted Therapy
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Breast Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Hormone Therapy
        • 9.3.3.2.3. By Targeted Therapy
        • 9.3.3.2.4. By End User

10. South America Breast Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Hormone Therapy
    • 10.2.3. By Targeted Therapy
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Breast Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Hormone Therapy
        • 10.3.1.2.3. By Targeted Therapy
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Breast Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Hormone Therapy
        • 10.3.2.2.3. By Targeted Therapy
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Breast Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Hormone Therapy
        • 10.3.3.2.3. By Targeted Therapy
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Breast Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Eli Lilly and Company
  • 15.5. Pfizer Inc.
  • 15.6. Merck & Co., Inc.
  • 15.7. Sanofi
  • 15.8. Eisai Co., Ltd.
  • 15.9. Bristol-Myers Squibb Company
  • 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer